Latest Breaking News On - Drug development center - Page 2 : comparemela.com

Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial

Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Jason lukeDrug development centerUniversity of pittsburgh school medicineHillman cancer centerCancer centerPittsburgh schoolNature medicine

Two-for-one cancer immunotherapy more effective and at least as safe as standard treatments

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.

Lily ramseyJason lukeDrug development centerUniversity of pittsburgh school medicineHillman cancer centerCancer centerPittsburgh schoolClinical trialAncer immunotherapyImmune system

Low-Dose Radiation Affects Cardiovascular Disease Risk in Human Aortic Endothelial Cells by Altering Gene Expression under Normal and Diabetic Conditions

#nuclear #Nuclear-free #anti-nuclear #NoNukes by Soo-Ho Lee 1,†, Ye Ji Jeong 1,†, Jeongwoo Park 1,2, Hyun-Yong Kim 1, Yeonghoon Son 1, Kwang Seok Kim 1, and Hae-June Lee 1, Divisions of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea 2 New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation, Daegu 41061, Korea Authors to whom correspondence should be addressed.…

Soult ukpyolsiSouth koreaChristina macphersonHyun yong kimJune leeMinji jeongDaegu gyeongbuk medical innovation foundationDivisions of radiation biomedical researchDrug development centerKorea institute of radiologicalHuman aortic endothelial cellsAltering gene expressionRadiation biomedical researchKorea instituteMedical sciencesSpecial issue

KEYNOTE-716: Primary melanoma, not lymph nodes, should drive therapeutic decision-making

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial

United statesMark leiserBymark leiserAstellas pharmaJasonj lukeBristol myers squibbDrug development centerNektar therapeuticsHillman cancer centerGilead sciencesMerck sharpModerna therapeuticsCancer center

Inside a Colombian Hellhole for Monkeys: Animals Left to Die of Wounds, Cages Full of Faeces - News

Inside a Colombian Hellhole for Monkeys: Animals Left to Die of Wounds, Cages Full of Faeces - News
peta.org.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from peta.org.au Daily Mail and Mail on Sunday newspapers.

Research modernisation dealCaucaseco scientific research centerDrug development centerMalaria vaccineHellhole apparently skirting requirementsIllegal capture